Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr838 Inhibitors

Olr838 inhibitors represent a fascinating class of chemical compounds that interact specifically with the Olr838 receptor, a member of the olfactory receptor (OR) family. These receptors, primarily found in the olfactory epithelium, are integral to the sense of smell. The inhibition of Olr838 entails a meticulous modulation of receptor activity, often involving the precise binding of inhibitors to the receptor's active site. This interaction typically leads to a conformational change in the receptor structure, thereby altering its signaling pathways. The intricate nature of this binding process is dictated by various factors such as the chemical structure of the inhibitor, the binding affinity, and the overall stability of the inhibitor-receptor complex.

From a structural chemistry perspective, Olr838 inhibitors are diverse, encompassing a wide range of molecular frameworks. These inhibitors often exhibit unique functional groups and structural motifs designed to optimize their interaction with the receptor. The design and synthesis of such inhibitors require a comprehensive understanding of the receptor's structure and the specific residues involved in ligand binding. Advanced techniques in computational chemistry, such as molecular docking and dynamic simulations, play a crucial role in predicting and optimizing the interactions between Olr838 and its inhibitors. Furthermore, spectroscopic methods, including NMR and X-ray crystallography, are essential for elucidating the detailed structural attributes of these complexes, offering insights into the precise mechanisms of inhibition. The study of Olr838 inhibitors not only advances our understanding of olfactory receptors but also contributes significantly to the broader field of chemical biology, highlighting the intricate interplay between small molecules and protein targets.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

BCR-ABL tyrosine kinase inhibitor, may disrupt signal transduction in cancer cells.

Sunitinib Malate

341031-54-7sc-220177
sc-220177A
sc-220177B
10 mg
100 mg
3 g
$193.00
$510.00
$1072.00
4
(1)

Multi-targeted receptor tyrosine kinase inhibitor, possibly affects angiogenesis and tumor growth.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Inhibitor of multiple kinases, could disrupt cell signaling and angiogenesis.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$92.00
$204.00
1
(1)

Inhibits MET, VEGFR2, and AXL, potentially affecting tumor growth and angiogenesis.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

MEK inhibitor, may impact cell proliferation and survival signaling pathways.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Proteasome inhibitor, potentially affects multiple cellular processes including cell cycle and apoptosis.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

mTOR inhibitor, could alter cell growth, proliferation, and survival pathways.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, may target specific mutations and alter signaling in cancer cells.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$116.00
$330.00
$510.00
$816.00
$1632.00
10
(0)

BCL-2 inhibitor, potentially influences apoptosis in cancer cells.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$205.00
$405.00
9
(1)

BCR-ABL tyrosine kinase inhibitor, could disrupt cellular signaling in chronic myeloid leukemia.